# M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

> **NCT06509906** · PHASE1 · TERMINATED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 3 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** M9466
- **DRUG:** Irinotecan
- **DRUG:** Folinic acid
- **DRUG:** Fluorouracil (5-FU)
- **DRUG:** Bevacizumab
- **DRUG:** Granulocyte colony stimulating factor (G-CSF)

## Key facts

- **NCT ID:** NCT06509906
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-10-08
- **Primary completion:** 2025-12-02
- **Final completion:** 2025-12-02
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2025-12-18

## Collaborators

- Merck KGaA, Darmstadt, Germany

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06509906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06509906, "M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06509906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*